Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,753 EUR | -0.11% | -.--% | -.--% |
Jul. 11 | Swiss Market Index in the Green; Barry Callebaut Plunges | MT |
Jul. 11 | Global markets live: Tesla, Citigroup, BP, Novo Nordisk, JPMorgan... |
Strengths
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- Analyst opinion has improved significantly over the past four months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company does not generate enough profits, which is an alarming weak point.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 29.97 times its estimated earnings per share for the ongoing year.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Food Processing
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-.--% | 9.73B | - | ||
+4.12% | 28.03B | B+ | ||
-8.22% | 2.11B | - | D | |
+3.77% | 1.41B | - | ||
-7.73% | 1.08B | - | C | |
+132.79% | 1.04B | B- | ||
+16.92% | 574M | B+ | ||
-22.77% | 392M | C+ | ||
0.00% | 227M | - | - | |
-11.20% | 220M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- BARN Stock
- BCLN Stock
- Ratings Barry Callebaut AG